Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.

Sato, Junichiro et al.·Scientific reports·2025·Preliminary Evidencelaboratory study (with case report)
RPEP-13433Laboratory study (with case report)Preliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
laboratory study (with case report)
Evidence
Preliminary Evidence
Sample
N=1 patient; in vitro cell line experiments
Participants
One acromegaly patient; pancreatic beta cell and intestinal L-cell lines

What This Study Found

Pasireotide caused severe blood sugar problems mainly by shutting down GLP-1 secretion. A GLP-1 analog worked better than a DPP-4 inhibitor to restore insulin release in both a patient and cell models.

Key Numbers

One patient with acromegaly switched from DPP-4 inhibitor to GLP-1 analog. In vitro: pasireotide blocked GLP-1 secretion via SSTR5-Gi pathway. GLP-1 partially restored insulin secretion in GLP-1R-MIN-6 cells.

How They Did This

Clinical case of drug switching plus in vitro experiments using MIN-6 beta cells stably expressing GLP-1R and GLUTag intestinal L-cells. Tested interactions between glucose, Gs-coupled receptor stimulation, and pasireotide.

Why This Research Matters

Pasireotide treats acromegaly but often causes hard-to-manage high blood sugar. This study clarifies why and suggests GLP-1 analogs as the better treatment choice.

What This Study Doesn't Tell Us

Single patient case. Cell line results may not fully reflect human physiology. No controlled clinical trial.

Trust & Context

Original Title:
Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.
Published In:
Scientific reports, 15(1), 9494 (2025)
Database ID:
RPEP-13433

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13433·https://rethinkpeptides.com/research/RPEP-13433

APA

Sato, Junichiro; Manaka, Katsunori; Horikoshi, Hirofumi; Taguchi, Maho; Harada, Kazuki; Tsuboi, Takashi; Nangaku, Masaomi; Iiri, Taroh; Makita, Noriko. (2025). Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.. Scientific reports, 15(1), 9494. https://doi.org/10.1038/s41598-025-90896-2

MLA

Sato, Junichiro, et al. "Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.." Scientific reports, 2025. https://doi.org/10.1038/s41598-025-90896-2

RethinkPeptides

RethinkPeptides Research Database. "Insights into GLP-1 and insulin secretion mechanisms in pasi..." RPEP-13433. Retrieved from https://rethinkpeptides.com/research/sato-2025-insights-into-glp1-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.